NEW YORK (GenomeWeb) – Protagen said today it is collaborating with Germany's National Center for Tumor Diseases (NCT) and NEC Laboratories Europe to improve approaches for in silico prediction of immunotherapy response in patients with malignant melanoma.

Under the collaboration, the parties will use machine learning approaches to develop biomarker models for immunotherapy endpoints, including adverse effects, clinical response, and survival.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.